[
  {
    "ts": null,
    "headline": "Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma",
    "summary": "Biogenâs disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated \"sell\" due to declining drug franchises.",
    "url": "https://finnhub.io/api/news?id=c1908ae121981d02b68da5bc073bf916f1b609732896126c3f308191022cd89a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739598908,
      "headline": "Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma",
      "id": 132715981,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187983228/image_2187983228.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogenâs disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated \"sell\" due to declining drug franchises.",
      "url": "https://finnhub.io/api/news?id=c1908ae121981d02b68da5bc073bf916f1b609732896126c3f308191022cd89a"
    }
  }
]